IBDEI0Q2 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11716,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11716,1,3,0)
 ;;=3^Rapidly progr neph synd w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,11716,1,4,0)
 ;;=4^N01.1
 ;;^UTILITY(U,$J,358.3,11716,2)
 ;;=^5015502
 ;;^UTILITY(U,$J,358.3,11717,0)
 ;;=N01.2^^46^573^66
 ;;^UTILITY(U,$J,358.3,11717,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11717,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,11717,1,4,0)
 ;;=4^N01.2
 ;;^UTILITY(U,$J,358.3,11717,2)
 ;;=^5015503
 ;;^UTILITY(U,$J,358.3,11718,0)
 ;;=N01.3^^46^573^64
 ;;^UTILITY(U,$J,358.3,11718,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11718,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11718,1,4,0)
 ;;=4^N01.3
 ;;^UTILITY(U,$J,358.3,11718,2)
 ;;=^5015504
 ;;^UTILITY(U,$J,358.3,11719,0)
 ;;=N01.4^^46^573^63
 ;;^UTILITY(U,$J,358.3,11719,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11719,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11719,1,4,0)
 ;;=4^N01.4
 ;;^UTILITY(U,$J,358.3,11719,2)
 ;;=^5015505
 ;;^UTILITY(U,$J,358.3,11720,0)
 ;;=N01.5^^46^573^67
 ;;^UTILITY(U,$J,358.3,11720,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11720,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,11720,1,4,0)
 ;;=4^N01.5
 ;;^UTILITY(U,$J,358.3,11720,2)
 ;;=^5015506
 ;;^UTILITY(U,$J,358.3,11721,0)
 ;;=N01.6^^46^573^62
 ;;^UTILITY(U,$J,358.3,11721,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11721,1,3,0)
 ;;=3^Rapidly progr neph synd w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,11721,1,4,0)
 ;;=4^N01.6
 ;;^UTILITY(U,$J,358.3,11721,2)
 ;;=^5015507
 ;;^UTILITY(U,$J,358.3,11722,0)
 ;;=N01.7^^46^573^65
 ;;^UTILITY(U,$J,358.3,11722,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11722,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,11722,1,4,0)
 ;;=4^N01.7
 ;;^UTILITY(U,$J,358.3,11722,2)
 ;;=^5015508
 ;;^UTILITY(U,$J,358.3,11723,0)
 ;;=N01.8^^46^573^70
 ;;^UTILITY(U,$J,358.3,11723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11723,1,3,0)
 ;;=3^Rapidly progr neph synd w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,11723,1,4,0)
 ;;=4^N01.8
 ;;^UTILITY(U,$J,358.3,11723,2)
 ;;=^5015509
 ;;^UTILITY(U,$J,358.3,11724,0)
 ;;=N01.9^^46^573^71
 ;;^UTILITY(U,$J,358.3,11724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11724,1,3,0)
 ;;=3^Rapidly progr neph synd w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,11724,1,4,0)
 ;;=4^N01.9
 ;;^UTILITY(U,$J,358.3,11724,2)
 ;;=^5015510
 ;;^UTILITY(U,$J,358.3,11725,0)
 ;;=N02.0^^46^573^79
 ;;^UTILITY(U,$J,358.3,11725,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11725,1,3,0)
 ;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,11725,1,4,0)
 ;;=4^N02.0
 ;;^UTILITY(U,$J,358.3,11725,2)
 ;;=^5015511
 ;;^UTILITY(U,$J,358.3,11726,0)
 ;;=N02.1^^46^573^78
 ;;^UTILITY(U,$J,358.3,11726,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11726,1,3,0)
 ;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,11726,1,4,0)
 ;;=4^N02.1
 ;;^UTILITY(U,$J,358.3,11726,2)
 ;;=^5015512
 ;;^UTILITY(U,$J,358.3,11727,0)
 ;;=N02.2^^46^573^76
 ;;^UTILITY(U,$J,358.3,11727,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11727,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
